Mineralys Therapeutics, Inc. (MLYS) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export MLYS earnings history in CSV or JSON format
Free sign-in required to download data
Mineralys Therapeutics, Inc. (MLYS) Earnings Overview
As of March 2, 2026, Mineralys Therapeutics, Inc. (MLYS) reported trailing twelve-month net income of -$171M, reflecting -0.8% year-over-year growth. The company earned $-2.43 per diluted share over the past four quarters.
Looking at the long-term picture, MLYS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2020.
Mineralys Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), MLYS has comparable earnings metrics. Compare MLYS vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$178M | -147.3% | -$192M | $-3.66 | - | - |
| 2023 | -$72M | -141.3% | -$85M | $-1.99 | - | - |
| 2022 | -$30M | -53.5% | -$31M | $-5.77 | - | - |
| 2021 | -$19M | -466.5% | -$19M | $-3.89 | - | - |
| 2020 | -$3M | - | -$3M | $-0.74 | - | - |
See MLYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLYS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MLYS vs AGIO
See how MLYS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is MLYS growing earnings?
MLYS EPS of $-2.43 reflects slowing growth at -0.8%, below the 5-year CAGR of N/A. TTM net income is $-171M. Expansion rate has moderated.
What are MLYS's profit margins?
Mineralys Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MLYS's earnings?
MLYS earnings data spans 2020-2024. The current earnings trend is -0.8% YoY. Historical data enables comparison across business cycles.